Search | Page 11 | Aplastic Anemia and MDS International Foundation

Search

Search results

  1. Acute Myeloid Leukemia (AML)

    ... able to tolerate toxic chemotherapy drugs. Drugs such as decitabine or azacitidine or hydroxyurea may be better tolerated by ...

    Topic section last updated 07/07/2016 - 3:15pm.

  2. Prognostic Relevance of the Kinetics of Worsening of Cytopenias in Lower-Risk MDS: A Substudy from the European Leukemianet Low Risk MDS (EUMDS) Registry

    ... (such as Vidaza® [ azacitidine ] or Dacogen® [ decitabine ]), a granulocyte colony-stimulating factor, hydroxyurea, ...

    Research Review last updated 05/02/2016 - 9:27am.

  3. Midostaurin and Azacitidine in Treating Elderly Patients With Acute Myelogenous Leukemia

    ... stem cell transplant Prior azacitidine , decitabine , or midostaurin Patients with known impairment of ...

    Clinical Trial last updated 06/03/2016 - 2:24pm.

  4. PRO#1278: Fludarabine and Busulfan vs. Fludarabine, Busulfan and Total Body Irradiation (FLUBUTBI)

    ... this study with the exception of lenalidomide , decitabine , azacitidine , imatinib mesylate, dasatinib, nilotinib ...

    Clinical Trial last updated 04/29/2016 - 3:09pm.

  5. Donor Stem Cell Transplant in Treating Patients With High Risk Acute Myeloid Leukemia

    ... treatment with demethylating agents (azacytidine or decitabine , lenalidomide , etc) ALLOWED. Cohort B: Patients who ...

    Clinical Trial last updated 06/13/2016 - 3:31pm.

  6. Shorter Course Tacrolimus After Nonmyeloablative, Related Donor BMT With High-dose Posttransplantation Cyclophosphamide

    ... , or an adequate course of 5- azacitidine or decitabine must have been given within 3 months prior to start of ...

    Clinical Trial last updated 05/02/2016 - 2:38pm.

  7. Therapies

    ... U.S. to treat MDS. Azacitidine (Vidaza®) and decitabine (Dacogen®) are approved to treat both low- and high-risk ...

    Page last updated 03/18/2016 - 11:26am.

  8. Incidence and Burden of the Myelodysplastic Syndromes

    ... therapy with hypomethlating agents (azacitidine and decitabine ) carry a poor prognosis.  These patients may be considered for ...

    Research Review last updated 05/02/2016 - 9:11am.

  9. Myelodysplastic syndromes: What do hospitalists need to know?

    ... agents such as azacitidine (Vidaza®) and decitabine (Dacogen®), intensive chemotherapy, and stem cell transplantation.  Patients tend to tolerate azacitidine and decitabine fairly well.  These agents appear to restore normal cell production ...

    Research Review last updated 05/02/2016 - 9:21am.

  10. Clinical Trial Basics

    ... marrow failure diseases. These include: decitabine (Dacogen) deferasirox (Exjade) ...

    Page last updated 03/29/2016 - 7:29pm.